PS
DFTX

Principal Securities’s Definium Therapeutics DFTX Stock Holding History

Principal Securities’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-58
Closed -$684 – 2675
2025
Q3 		$684 Hold
58
– – ﹤0.01% 3480
2025
Q2 		$376 Buy
+58
New +$381 ﹤0.01% 3527

Other funds holding DFTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

Principal Securities's DFTX Position: Q4 2025 in Review

Principal Securities sold out of Definium Therapeutics (DFTX) in Q4 2025, closing a stake of 58 shares — an estimated $684 sold.

Principal Securities first reported a position in DFTX in Q2 2025 and held it in 2 quarters. The position peaked at $684 in Q3 2025. 208 funds tracked by Wall St. Rank hold DFTX as of Q4 2025.

  • Principal Securities reported no remaining Definium Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Principal Securities sold 58 Definium Therapeutics shares in Q4 2025, an estimated $684.
  • Principal Securities first reported a position in Definium Therapeutics in Q2 2025 and held it in 2 quarters.
  • Principal Securities's Definium Therapeutics position peaked at $684 in Q3 2025.
  • 208 funds tracked by Wall St. Rank held Definium Therapeutics as of Q4 2025.

Based on Principal Securities's 13F filing for Q4 2025, filed 12 Feb 2026.